Basic Information

Gene symbol LAMP3 Synonyms CD208, DC LAMP, DC-LAMP, DCLAMP, LAMP, LAMP-3, TSC403 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description lysosomal associated membrane protein 3

Gene symbol UL83 Synonyms None Type of gene protein-coding
Description tegument protein pp65

GTO ID GTC0256
Trial ID NCT02529072
Disease Astrocytoma | Glioblastoma
Altered gene UL83|LAMP
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment DC Vaccine
Co-treatment nivolumab
PhasePhase1
Recruitment statusCompleted
TitleAVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors
Year2016
CountryUnited States
Company sponsorGary Archer Ph.D.
Other ID(s)Pro00065241
Vector information
Vectordendritic cell

Clinical Result

Cohort1: nivolumab,3 mg/kg,every 2 weeks for 8 weeks
Administration route intravenous injection|intradermal injection
Dosage Nivolumab, 3 mg/kg, every 2 weeks for 8 weeks; surgery; nivolumab and DC vaccine, every 2 weeks (± 1) for a total of 3 vaccine; nivolumab biweekly, DC vaccinations for a total of 5 more vaccines
Pts 3
Age Adult, Older_Adult
Outcome The Safety of Administering DC Vaccines With Nivolumab:Measure Type: Number:0
Adverse reactions 3/3(All-cause mortality); 1/3(Nervous system disorders; Vascular disorders)
Cohort2: nivolumab,fourth cycle
Administration route intravenous injection|intradermal injection
Dosage Nivolumab, fourth cycle; Nivolumab 3 mg/kg, DC vaccine every 2 weeks for a total of 3 vaccines; surgery; nivolumab, biweekly, DC vaccinations, monthly for a total of 5 more vaccines
Pts 3
Age Adult, Older_Adult
Outcome The Safety of Administering DC Vaccines With Nivolumab:Measure Type: Number:0
Adverse reactions 2/3(All-cause mortality); 2/3(Infections and infestations; Injury, poisoning and procedural complications)

Relationship Graph

Overview of Knowledge Graph